Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Speciality MedicinesBOM:544738 -6.76%21 Return-on-Tangible-Equity is 32.27% as of Mar. 2026, which is 2% above its 10-year median of 31.78. GuruFocus rates BOM:544738 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 897 Drug Manufacturers companies, Speciality Medicines ranks better than 72.13% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Speciality Medicines's annualized net income for the quarter that ended in Mar. 2026 was ₹163.7 Mil. Speciality Medicines's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹507.1 Mil. Therefore, Speciality Medicines's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 32.27%.
The historical rank and industry rank for Speciality Medicines's Return-on-Tangible-Equity or its related term are showing as below:
BOM:544738'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 16.14 Med: 31.78 Max: 79.55
Current: 16.14
During the past 5 years, Speciality Medicines's highest Return-on-Tangible-Equity was 79.55%. The lowest was 16.14%. And the median was 31.78%.
BOM:544738's Return-on-Tangible-Equity is ranked better than 72.13% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.68
vs BOM:544738: 16.14
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Speciality Medicines Return-on-Tangible-Equity Related Terms
Speciality Medicines Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Speciality Medicines's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544738 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Speciality Medicines's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Speciality Medicines Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Speciality Medicines's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Speciality Medicines's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 32.27% mean?
Speciality Medicines (BOM:544738) has a Return-on-Tangible-Equity of 32.27% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Speciality Medicines and its competitors. This is near median its historical median of 31.78. Over the past decade, Speciality Medicines' Return-on-Tangible-Equity has ranged from 16.14 to 79.55. According to the industry distribution chart, Speciality Medicines ranks #250 out of 897 companies in the Drug Manufacturers industry, placing it in the top 27.9%.
Is Speciality Medicines' Return-on-Tangible-Equity too high?
Speciality Medicines' current Return-on-Tangible-Equity of 32.27% is near median its 10-year median of 31.78. Over the past 10 years, this metric has ranged from a low of 16.14 to a high of 79.55. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.68. Speciality Medicines' value of 32.27% is 320.2% above this industry median. Based on the distribution chart, Speciality Medicines ranks #250 out of 897 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Speciality Medicines has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Speciality Medicines' Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Speciality Medicines ranks #250 out of 897 companies for Return-on-Tangible-Equity. This puts Speciality Medicines in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.68. Speciality Medicines' value of 32.27% is 320.2% above this benchmark. Historically, Speciality Medicines' own Return-on-Tangible-Equity has ranged from 16.14 to 79.55 over the past decade. While the company's 10-year median is 31.78 vs. the industry median of 7.68, Speciality Medicines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.68, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Speciality Medicines's current Return-on-Tangible-Equity of 32.27% is 320.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Speciality Medicines and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Speciality Medicines's current Return-on-Tangible-Equity is 32.27%, which is near median its own 10-year median of 31.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Speciality Medicines stock overvalued right now?
Speciality Medicines (BOM:544738) has a current Return-on-Tangible-Equity of 32.27%. The current Return-on-Tangible-Equity is 32.27%, which is near median its 10-year median of 31.78 and 320.2% above the Drug Manufacturers industry median of 7.68. Speciality Medicines' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Speciality Medicines (BOM:544738), the current Return-on-Tangible-Equity is 32.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Speciality Medicines Ltd is engaged in the marketing and distribution of finished formulations of specialty pharmaceutical products, comprising oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases. Its product range includes various dosage forms such as tablets, capsules, syrups, injections, infusions, inhalers, sprays, and topical formulations. The company operates through two business models: (a) Manufacturing, through contract manufacturing basis, and (b) Marketing and distribution of specialty pharmaceutical products sourced from manufacturers. The majority of the company's revenue is derived from the sale of its projects, mainly through exports to other countries.
21GF Score
Get the complete analysis for BOM:544738
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544738 has been successfully added to your 
